Back to top

Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating today. Soumit Roy’s rating is based on the p...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Janux Therapeutics, Inc. (JANX)